All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Approval Sought for Lenvatinib in Differentiated Thyroid Cancer

August 31st 2014

Eisai has submitted a New Drug Application for lenvatinib (E7080) as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), based on findings from the phase III SELECT trial that was presented at the 2014 ASCO Annual Meeting.

Advaxis Scientific Officer Illuminates ADXS-PSA/Pembrolizumab Collaborative Study

August 30th 2014

Robert Petit, PhD, the chief scientific officer at Advaxis, provides insight into the ADXS-PSA immunotherapy and the rationale behind the combination study with pembrolizumab.

Pembrolizumab Combination Study Planned in Prostate Cancer

August 27th 2014

Advaxis and Merck have entered into a clinical trial collaboration agreement to evaluate the combination of two novel immunotherapies for the treatment of patients with metastatic castration-resistant prostate cancer.

CAR T Cell Therapy Effective in Advanced B-cell Malignancies

August 26th 2014

Treatment with KTE-C19, a CD19-targeted CAR-modified T cell therapy, demonstrated an objective response rate of 92% in patients with advanced B-cell malignancies.

FDA Approves Eltrombopag for Severe Aplastic Anemia

August 26th 2014

The FDA has approved eltrombopag as a treatment for patients with severe aplastic anemia following an insufficient response to immunosuppressive therapy.

Increased Medicaid Payments for Office Visits Results in More Screening for Cancer

August 26th 2014

Medicaid patients in states that pay more for office visits had an increased likelihood of being screened for cancer, according to results of a study published in CANCER.

Report Identifies Shortfalls in Medicare Accountability Model

August 25th 2014

How much physicians get paid is increasingly determined by a payment formula that penalizes doctors whose patients are more expensive-even when those higher costs stem from services that other doctors perform says a new report from the Center for Healthcare Quality and Payment Reform.

Pharma Collaborations Abound Across Oncology

August 21st 2014

A number of large pharmaceutical companies have forged clinical trial collaborations focused on the investigation of novel combinations and companion diagnostics across multiple cancer indications.

Lenalidomide Plus R-CHOP Effective in Aggressive DLBCL Subtype

August 19th 2014

The addition of lenalidomide to R-CHOP demonstrated promising efficacy in previously untreated patients with diffuse large B-cell lymphoma across all subtypes of the disease.

Using Technology to Improve Patient Fee Collection Rates

August 19th 2014

Although the Affordable Care Act (ACA) made accessibility to health insurance easier, consumers are finding themselves shouldering greater out-of-pocket costs in the form of copayments and deductibles for the care that they receive. Physicians are also feeling the need to collect more fees from more of their patients.

Medicare to Pay Docs for Chronic Care Coordination

August 18th 2014

Starting in January 2015, Medicare will begin paying physicians for the care coordination they provide beneficiaries with chronic conditions.

Pfizer Seeks FDA Approval for Palbociclib

August 18th 2014

Pfizer has submitted a New Drug Application for palbociclib plus letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative advanced breast cancer, based on findings from the phase II PALOMA-1 trial.

Medicaid and Uninsured Patients More Likely to Present With Advanced Disease

August 15th 2014

Patients with Medicaid insurance and those without insurance were more likely to present with distant disease than patients with private insurance, according to results presented in the Journal of Clinical Oncology.

FDA Approves Bevacizumab for Advanced Cervical Cancer

August 14th 2014

The FDA has approved bevacizumab in combination with paclitaxel and cisplatin or paclitaxel and topotecan as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.

Carfilzomib Monotherapy Misses Survival Endpoint in Heavily Pretreated Myeloma

August 14th 2014

Treatment with single-agent carfilzomib (Kyprolis) was unable to significantly extend overall survival (OS) compared with best supportive care in heavily pretreated patients with multiple myeloma

Favorable Safety Profile of T-DM1 Confirmed in Large Study

August 13th 2014

The favorable safety profile of T-DM1 makes it apt to be looked at in other settings of breast cancer.

Tripathy Offers Perspective on HER2-Positive Breast Cancer

August 13th 2014

The ever-evolving treatment landscape for patients with HER2-positive breast cancer leaves several questions unanswered regarding therapeutic sequences and whether an optimal standard of care exists.

FDA Approves First DNA-Based CRC Screening Tool

August 12th 2014

The FDA has approved the noninvasive stool-based DNA test Cologuard for the detection of colorectal cancer or cancer precursors in asymptomatic patients at average risk.

First-Year Results Reported for Michigan Oncology Medical Home Pilot Program

August 12th 2014

A multipractice oncology medical home model, the Michigan Oncology Medical Home Demonstration Project (MOMHDP), reported preliminary first-year results that tallied an estimated savings per patient of $550.33, according to an abstract in the Journal of Oncology Practice.

Florida ACO Reports a $22 Million Savings

August 12th 2014

A Florida accountable care organization (ACO) is reporting $22 million in savings during its first year, with a shared savings of $11 million.